ESMO: European Society for Medical Oncology

  1. Results fromtheTARGET, I-PREDICT and WINTHER studies released
  2. Approval is based on results from the KEYNOTE‑426 study
  3. Innovative breast cancer treatment will be discussed during the first ESMO Breast Cancer Congress in Berlin
  4. Systemic absorption is of concern because it may result in side effects such as venous thromboembolism, stroke and endometrial cancer
  5. Approval of FGFR inhibitor is based on data from a cohort of patients enrolled on Study BLC2001